Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Barbour

Showing results (281-290 of 296) with videos related to

Pageof 30
Sort By:
Kidney International Reports|August 11, 2020
Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental GlomerulosclerosisDebbie S Gipson, Michelle A Hladunewich, Richard Lafayette, et al.
The New England Journal of Medicine|November 6, 2025
A Phase 3 Trial of Atacicept in Patients with IgA NephropathyRichard Lafayette, Sean J Barbour, Robert M Brenner, et al.
Canadian Journal of Kidney Health and Disease|April 22, 2022
The Canadian Glomerulonephritis Registry (CGNR) and Translational Research Initiative: Rationale and Clinical Research ProtocolAinslie M Hildebrand, Moumita Barua, Sean J Barbour, et al.
Clinical Pharmacokinetics|February 15, 2021
Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney DiseaseAnnemarie B van der Aart-van der Beek, Jeroen V Koomen, Claire C J Dekkers, et al.
JCI Insight|February 8, 2022
Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responsesElissa G Currie, Bryan Coburn, Elisa A Porfilio, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 1, 2022
Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative GlomerulonephritisHannah J Lomax-Browne, Nicholas R Medjeral-Thomas, Sean J Barbour, et al.
Kidney International|May 25, 2019
Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular diseaseSimon A Carter, Liz Lightstone, Daniel Cattran, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 31, 2021
A Core Outcome Set for Trials in Glomerular Disease: A Report of the Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD) Stakeholder WorkshopsSimon A Carter, Liz Lightstone, Dan Cattran, et al.
Kidney International|May 8, 2021
Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular diseaseSimon A Carter, Charlotte Logeman, Martin Howell, et al.
Nephron|June 20, 2015
A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR)Fernando C Fervenza, Pietro A Canetta, Sean J Barbour, et al.
Pageof 30

Showing results (281-290 of 296) with videos related to

Sort By:
Pageof 30
Kidney International Reports|August 11, 2020
Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental GlomerulosclerosisDebbie S Gipson, Michelle A Hladunewich, Richard Lafayette, et al.
The New England Journal of Medicine|November 6, 2025
A Phase 3 Trial of Atacicept in Patients with IgA NephropathyRichard Lafayette, Sean J Barbour, Robert M Brenner, et al.
Canadian Journal of Kidney Health and Disease|April 22, 2022
The Canadian Glomerulonephritis Registry (CGNR) and Translational Research Initiative: Rationale and Clinical Research ProtocolAinslie M Hildebrand, Moumita Barua, Sean J Barbour, et al.
Clinical Pharmacokinetics|February 15, 2021
Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney DiseaseAnnemarie B van der Aart-van der Beek, Jeroen V Koomen, Claire C J Dekkers, et al.
JCI Insight|February 8, 2022
Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responsesElissa G Currie, Bryan Coburn, Elisa A Porfilio, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 1, 2022
Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative GlomerulonephritisHannah J Lomax-Browne, Nicholas R Medjeral-Thomas, Sean J Barbour, et al.
Kidney International|May 25, 2019
Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular diseaseSimon A Carter, Liz Lightstone, Daniel Cattran, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 31, 2021
A Core Outcome Set for Trials in Glomerular Disease: A Report of the Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD) Stakeholder WorkshopsSimon A Carter, Liz Lightstone, Dan Cattran, et al.
Kidney International|May 8, 2021
Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular diseaseSimon A Carter, Charlotte Logeman, Martin Howell, et al.
Nephron|June 20, 2015
A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR)Fernando C Fervenza, Pietro A Canetta, Sean J Barbour, et al.
Pageof 30